Gastric and Esophageal
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
- Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics
- Principal Investigator: Nina Kadan-Lottick
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
- Disease/Condition: Other Digestive Organ
- Principal Investigator: Stacey M Stein
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
- Principal Investigator: Hari Anant Deshpande
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
- Disease/Condition: Other Digestive Organ | Stomach
- Principal Investigator: Jill Lacy
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
- Disease/Condition: Other Digestive Organ | Pancreas | Stomach
- Principal Investigator: Stacey M Stein
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
- Disease/Condition: Esophagus | Other Digestive Organ | Stomach
- Principal Investigator: Stacey M Stein
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
- Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
- Principal Investigator: Patricia LoRusso
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
- Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Mycosis Fungoides | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
- Principal Investigator: Patricia LoRusso
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
- Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I
- Principal Investigator: Patricia LoRusso
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
- Disease/Condition: Eye and Orbit | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I | Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus
- Principal Investigator: Patricia LoRusso